{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:33:04Z","timestamp":1794357184014,"version":"4.9.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s12325-023-02758-w","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T07:02:26Z","timestamp":1704870146000},"page":"885-890","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bladder Cancer, Loss of Y\u00a0Chromosome, and New Opportunities for Immunotherapy"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9398-9713","authenticated-orcid":false,"given":"Arun K.","family":"Mankan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagender","family":"Mankan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Begona","family":"de las Heras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakti H.","family":"Ramkissoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Bodriagova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6301-3309","authenticated-orcid":false,"given":"Kamal S.","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"issue":"3","key":"2758_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2758_CR2","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3390\/cancers12051181","volume":"12","author":"M Wo\u0142\u0105cewicz","year":"2020","unstructured":"Wo\u0142\u0105cewicz M, Hrynkiewicz R, Grywalska E, et al. Immunotherapy in bladder cancer: current methods and future perspectives. Cancers (Basel). 2020;12(5):1181.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"2758_CR3","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00262-023-03376-9","volume":"72","author":"A Semeniuk-Wojta\u015b","year":"2023","unstructured":"Semeniuk-Wojta\u015b A, Podd\u0119bniak-Strama K, Modzelewska M, et al. Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer. Cancer Immunol Immunother. 2023;72(7):1971\u201389.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"2758_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.25259\/IJMS_159_2020","volume":"73","author":"V Mishra","year":"2021","unstructured":"Mishra V, Balasubramaniam G. Urinary bladder cancer and its associated factors\u2013an epidemiological overview. Indian J Med Sci. 2021;73(2):239\u201348.","journal-title":"Indian J Med Sci"},{"key":"2758_CR5","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-023-06234-x","volume":"619","author":"HA Abdel-Hafiz","year":"2023","unstructured":"Abdel-Hafiz HA, Schafer JM, Chen X, et al. Y chromosome loss in cancer drives growth by evasion of adaptive immunity. Nature. 2023;619:624\u201331.","journal-title":"Nature"},{"issue":"3","key":"2758_CR6","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(3):244\u201358.","journal-title":"Ann Oncol"},{"issue":"13","key":"2758_CR7","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218\u201330.","journal-title":"N Engl J Med"},{"key":"2758_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-016-1110-1","volume":"17","author":"R Acuna-Hidalgo","year":"2016","unstructured":"Acuna-Hidalgo R, Veltman JA, Hoischen A. New insights into the generation and role of de novo mutations in health and disease. Genome Biol. 2016;17:1\u201319.","journal-title":"Genome Biol"},{"issue":"4","key":"2758_CR9","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3109\/00313021003767298","volume":"42","author":"S Minner","year":"2010","unstructured":"Minner S, Kilgu\u00e9 A, Stahl P, et al. Y chromosome loss is a frequent early event in urothelial bladder cancer. Pathology. 2010;42(4):356\u20139.","journal-title":"Pathology"},{"issue":"11","key":"2758_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1501662","volume":"2","author":"LP Blair","year":"2016","unstructured":"Blair LP, Liu Z, Labitigan RLD, et al. KDM5 lysine demethylases are involved in maintenance of 3\u2032 UTR length. Sci Adv. 2016;2(11):e1501662.","journal-title":"Sci Adv"},{"issue":"19","key":"2758_CR11","doi-asserted-by":"publisher","first-page":"7096","DOI":"10.1073\/pnas.1324036111","volume":"111","author":"X Li","year":"2014","unstructured":"Li X, Liu L, Yang S, et al. Histone demethylase KDM5B is a key regulator of genome stability. Proc Natl Acad Sci. 2014;111(19):7096\u2013101.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"2758_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13072-023-00483-w","volume":"16","author":"M Zhu","year":"2023","unstructured":"Zhu M, Zhang R-N, Zhang H, et al. PCGF6\/MAX\/KDM5D facilitates MAZ\/CDK4 axis expression and pRCC progression by hypomethylation of the DNA promoter. Epigenetics Chromatin. 2023;16(1):9.","journal-title":"Epigenetics Chromatin"},{"key":"2758_CR13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2741\/e830","volume":"10","author":"R Patel","year":"2018","unstructured":"Patel R, Khalifa AO, Isali I, Shukla S. Prostate cancer susceptibility and growth linked to Y chromosome genes. Front Biosci (Elite Ed). 2018;10:423.","journal-title":"Front Biosci (Elite Ed)"},{"key":"2758_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","volume":"69","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto M, Kamphorst AO, Im SJ, et al. CD8 T\u00a0cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu Rev Med. 2018;69:301\u201318.","journal-title":"Annu Rev Med"},{"issue":"12","key":"2758_CR15","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1093\/annonc\/mdx518","volume":"28","author":"A Necchi","year":"2017","unstructured":"Necchi A, Joseph RW, Loriot Y, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Ann Oncol. 2017;28(12):3044\u201350.","journal-title":"Ann Oncol"},{"issue":"9","key":"2758_CR16","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1007\/s00262-023-03469-5","volume":"72","author":"M Santoni","year":"2023","unstructured":"Santoni M, Myint ZW, Buttner T, et al. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study. Cancer Immunol Immunother. 2023;72(9):2961\u201370.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2758_CR17","doi-asserted-by":"publisher","first-page":"e003231","DOI":"10.1136\/jitc-2021-003231","volume":"10","author":"MR Franklin","year":"2022","unstructured":"Franklin MR, Platero S, Saini KS, Curigliano G, Anderson S. Immuno-oncology trends: preclinical models, biomarkers, and clinical development. J Immunother Cancer. 2022;10(1):e003231.","journal-title":"J Immunother Cancer"},{"key":"2758_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100713","volume":"36","author":"I Salifu","year":"2023","unstructured":"Salifu I, Singh N, Berraondo M, et al. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer. Cancer Treat Res Commun. 2023;36: 100713.","journal-title":"Cancer Treat Res Commun"},{"issue":"7","key":"2758_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1080\/14712598.2021.1936494","volume":"21","author":"KS Saini","year":"2021","unstructured":"Saini KS, Punie K, Twelves C, et al. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. Expert Opin Biol Ther. 2021;21(7):945\u201362.","journal-title":"Expert Opin Biol Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02758-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02758-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02758-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T18:14:04Z","timestamp":1708452844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02758-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2758"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02758-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"1 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Arun K Mankan, Begona de las Heras, Olga Bodriagova, Laura Vidal, and Kamal S. Saini are employed by Fortrea Inc. Shakti H. Ramkissoon is employed by Labcorp Drug Development Inc. Nagender Mankan is employed by Northwest Georgia Oncology Centers, Roswell, Georgia, USA. Enrique Grande works at MD Anderson Cancer Center Madrid, Madrid, Spain. All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Kamal S Saini reports consulting fees from the European Commission, and stock and\/or other ownership interests in Fortrea Inc. and Quantum Health Analytics (UK) Ltd., outside the submitted work. Enrique Grande has provided consulting\/advisory services for MSD, Pfizer, Ipsen, Roche, Bristol-Myers Squibb, has received honoraria from Pfizer, Bristol-Myers Squibb, Ipsen, Roche, Eisai, Eusa Pharma, MSD, Genzyme, Advanced Accelerator Applications, Novartis, Pierre Fabre, Lexicon, Celgene, Janssen-Cilag, Astellas Pharma, AstraZeneca, and Lilly, and has received travel\/accommodations\/expenses from Bristol-Myers Squibb, Roche\/Genentech, Pfizer, Janssen-Cilag, and Ipsen and has received research funding from Roche, Pfizer, AstraZeneca, Ipsen, Molecular Templates, Lexicon, Astellas Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}